Publications

New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01 E and BCG-revaccination.

Clark, RA; Weerasuriya, CK; Portnoy, A; Mukandavire, C; Quaife, M; Bakker, R; SCARPONI, D; Harris, RC; Rade, K; Mattoo, SK; Tumu, D; Menzies, NA; WHITE, RG;

2023

medRxiv (2023). 10.1101/2023.02.24.23286406.

Bias assessment of a test-negative design study of COVID-19 vaccine effectiveness used in national policymaking.

GRAHAM, S; Tessier, E; Stowe, J; Bernal, JL; PARKER, EP K; NITSCH, D; MILLER, E; Andrews, N; Walker, JL; McDonald, HI;

2023

Nature communications, (2023).14 1 10.1038/s41467-023-39674-0.

Cost-effectiveness of tuberculosis infection prevention and control interventions in South African clinics: a model-based economic evaluation informed by complexity science methods.

BOZZANI, FM; MCCREESH, N; Diaconu, K; GOVENDER, I; WHITE, RG; Kielmann, K; GRANT, AD; VASSALL, A;

2023

BMJ Global Health, (2023).8 2 10.1136/bmjgh-2022-010306.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.

Portnoy, A; CLARK, RA; Quaife, M; WEERASURIYA, CK; Mukandavire, C; Bakker, R; Deol, AK; Malhotra, S; Gebreselassie, N; Zignol, M; Sim, SY; Hutubessy, RC W; Baena, IG; Nishikiori, N; JIT, M; WHITE, RG; Menzies, NA;

2023

PLOS Medicine, (2023).20 1 10.1371/journal.pmed.1004155.

First dose COVID-19 vaccine coverage amongst adolescents and children in England: an analysis of 3.21 million patients' primary care records in situ using OpenSAFELY.

Hopcroft, L; Curtis, H; Brown, A; Hulme, W; Andrews, C; Morton, C; Inglesby, P; Morley, J; Mehrkar, A; Bacon, S; EGGO, R; MAHALINGASIVAM, V; PARKER, E; TOMLINSON, L; Bates, C; Cockburn, J; Parry, J; Hester, F; Harper, S; GOLDACRE, B; Walker, A; MacKenna, B;

2023

Wellcome Open Res (2023). 10.12688/wellcomeopenres.18735.2.

Challenges in estimating waning effectiveness of two doses of BNT162b2 and ChAdOx1 COVID-19 vaccines beyond six months: an OpenSAFELY cohort study using linked electronic health records.

Horne, EM F; Hulme, W; KEOGH, R; Palmer, T; WILLIAMSON, E; PARKER, EP K; Walker, V; Knight, R; Wei, Y; Taylor, K; Fisher, L; Morley, J; Mehrkar, A; Dillingham, I; Bacon, S; GOLDACRE, B; Sterne, JA C; The OpenSAFELY Collaborative,;

2023

medRxiv (2023). 10.1101/2023.01.04.22283762.

Safety, immunogenicity, and effectiveness of COVID-19 vaccines for pregnant persons: A protocol for systematic review and meta analysis.

Ciapponi, A; Berrueta, M; Ballivian, J; Bardach, A; Mazzoni, A; Anderson, S; Argento, FJ; Bok, K; Comandé, D; Goucher, E; KAMPMANN, B; PARKER, EP K; Rodriguez-Cairoli, F; Santa Maria, V; Stergachis, A; Voss, G; Xiong, X; Zaraa, S; Munoz, FM; Karron, RA; Gottlieb, SL; Buekens, PM;

2023

Medicine, (2023).102 9 10.1097/MD.0000000000032954.

Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.

Mwenda, V; Jalang'o, R; Miano, C; Bor, J-P; Nyangasi, M; Mecca, L; Were, V; Kariithi, E; Pecenka, C; Schuind, A; ABBAS, K; CLARK, A;

2023

Vaccine, (2023).41 29 10.1016/j.vaccine.2023.05.019.

Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP.

Hulme, WJ; Horne, EM F; PARKER, EP K; KEOGH, RH; WILLIAMSON, EJ; Walker, V; Palmer, TM; Curtis, HJ; Walker, AJ; Andrews, CD; Mehrkar, A; Morley, J; MacKenna, B; Bacon, SC J; GOLDACRE, B; Hernán, MA; Sterne, JA C;

2023

BMJ, (2023).380, 10.1136/bmj-2022-072808.

Modeling the potential health impact of prospective Strep A vaccines.

Giannini, F; Cannon, JW; Cadarette, D; Bloom, DE; Moore, HC; Carapetis, J; ABBAS, K;

2023

NPJ vaccines, (2023).8 1 10.1038/s41541-023-00668-0.